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Contrast-Enhanced Harmonic
Ultrasonography for the Assessment of
Prostate Cancer Aggressiveness: a
Preliminary Study
Objective: To determine whether contrast-enhanced harmonic ultrasonogra-
phy can be used to predict the aggressiveness of prostate cancer. 
Materials and Methods: Contrast-enhanced harmonic ultrasonography was
performed in 103 patients suspected of prostate cancer before biopsy. Time
intensity curves were reconstructed for systematic biopsy sites and sonographic
abnormalities. The characteristics of the curves were described using hemody-
namic indices including arrival time (AT), time-to-peak (TTP), and peak intensity
(PI). The differences of hemodynamic indices between high-grade and low-grade
cancer were analyzed and the correlations between the hemodynamic indices
and biopsy Gleason score were studied. 
Results: Prostate cancer was detected in 41 of 103 patients and there were
significant differences in the hemodynamic indices between the biopsy sites of
the non-malignant patients and prostate cancer lesions (p < 0.05). The prostate
biopsies revealed 154 prostate cancer lesions, including 31 low-grade lesions
and 123 high-grade lesions. The hemodynamic indices AT and TTP of high-
grade tumors were significantly shorter than those of low-grade tumors (p =
0.001, 0.002). In addition, high-grade peripheral zone (PZ) tumors had higher PI
than low-grade PZ tumors (p = 0.009). The PZ prostate cancer Gleason score
correlated with PI, AT and TTP, with Spearman correlation coefficients of 0.223, 
-0.335, and -0.351, respectively (p = 0.013, < 0.001 and < 0.001).
Conclusion: Contrast-enhanced ultrasound measurements of hemodynamic
indices correlate with the prostate cancer Gleason score. 
n patients with prostate cancer, the accurate assessment of tumor aggres-
siveness is important in the treatment decision-making and prognosis
prediction. A prostate biopsy Gleason score is widely used in assessing
prostate cancer aggressiveness. Recent studies have found that prostate cancer lesions
with higher Gleason scores had a higher degree of vascularity (1, 2). Thus, an imaging
protocol which can assess microvasculature will be useful in predicting prostate cancer
Gleason score noninvasively.
Microbubble contrast agents provide a practical solution to the problem of imaging
microvasculature in the prostate (3-6). With contrast-enhanced targeted biopsy, the
prostate cancer detection rate can be improved with fewer cores (7-9). Also, another
study found that contrast-enhanced ultrasonography was more sensitive in detecting
higher grade tumors (10) and the author suggested that contrast-enhanced ultrasound
might be helpful in grading the prostate cancer. In this paper, contrast-enhanced
harmonic ultrasonography was employed to facilitate an accurate analysis of the time
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Istudy is to determine whether contrast-enhanced
ultrasonography and the hemodynamic parameter is useful
in predicting prostate cancer Gleason score. 
MATERIALS AND METHODS
Study Population
The study was performed according to the ethical
standards of the Institutional Review Board, and informed
consent was obtained from each patient. A total of 103
consecutive male subjects underwent transrectal
ultrasound-guided prostate biopsies for the first time due to
either abnormal digital rectal examination findings or
elevated serum prostate specific antigen (PSA) levels ( 4
ng/ml). A contrast-enhanced ultrasonography was
performed for each patient before the biopsy. 
Imaging Protocol
A radiologist with 10 years experience in performing
transrectal ultrasound and prostate biopsies performed all
the ultrasonography examinations with the Sequoia 512
(Siemens Medical Solutions, Mountain View, CA)
ultrasonography system equipped with EV8C4-S end-fire
probe. All patients were examined in the left lateral
decubitus position. Gray-scale imaging was performed with
a probe frequency of 7.0 MHz, a dynamic range of 80 dB.
For color Doppler ultrasonography, the probe frequency
was 6.0 MHz, the color Doppler gain was adjusted to
maximize the signal but eliminate color noise from the
tissue of the prostate, and the color Doppler window was
set to include the entire gland. After the baseline
ultrasonography, a contrast-enhanced ultrasonography was
performed using cadence contrast pulse sequencing (CPS)
mode, with a probe frequency of 8.0 MHz, a dynamic
range of 81 dB, a mechanical index of 0.11, and a CPS
gain setting with automatic optimizing. For contrast-
enhanced ultrasonography, two planes were scanned for
each patient: one being the transverse plane of maximal
width; the other was the transverse plane of the
sonographic abnormality, or the most hypervascular plane
on color Doppler imaging for patients with no suspicion of
prostate cancer on baseline ultrasonography. For further
spatial correlation within the biopsy site, the contrast
imaging plane was saved using internal and external
anatomic landmarks for references (i.e., veromontanum,
external sphincter, surgical and anatomic capsule, urethra,
neurovascular bundle, hypertrophic gland nodules, seminal
vesicle, and hypoechoic lesions). The entire examination
was saved in DICOM (digital imaging and communications
in medicine) format and transmitted to a workstation for
further analysis.
Contrast Infusion
Contrast-enhanced imaging was performed during the
injection of a sulphur hexafluoride microbubble (SonoVue,
Bracco, Italy) at a concentration of 8 ul/ml. A volume of
2.4 ml contrast agent was administered for each contrast
plane. In addition a total volume of 4.8 ml contrast agent
was administered to each patient for two contrast planes.
The contrast agent was administered as a bolus via an
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Fig. 1. Figures showing biopsy procedure.
A. Postcontrast image of prostate gland of 68-year-old man with elevated prostate specific antigen level of 6.85 ng/ml. Substantial
enhancement and earlier arrival of contrast-enhanced blood were observed in lateral part of left peripheral zone (arrow). 
B. During biopsy, biplane probe was rotated to sagittal plane of area showing abnormal findings using anatomic landmarks as reference,
after biopsy gun was fired, probe was switched to convex transducer. Biopsy site (black arrow, comet tail sign) was determined precisely
at area showing abnormal findings. Biopsy revealed prostate lesion with Gleason score of 4 + 3. 
ABantecubital vein of the right arm. Immediately after
contrast injection, 5 ml of 0.9% sodium chloride was
injected to clear the intravenous cannula.
Biopsy Protocol and Histopathologic Analysis 
Prior to the biopsy, all patients underwent an evaluation
for blood coagulation, urine analysis, and electrocardio-
gram. Anticoagulant therapy was stopped seven days
before the procedure. In addition, prophylactic antibiotic
coverage was not provided routinely except for patients
with high risk of urinary tract infection, in which case, they
would be provided with fluoroquinolone for three days
beginning from the day before the biopsy. After the
completion of the ultrasound examination, the ultrasound-
guided transperineal prostate biopsies were performed
using a Technos MPX (ESAOTE, Italy) scanner with a
TRT23 biplane probe by two radiologists. Both the octant
systematic biopsies and targeted biopsies were taken with
a spring-loaded biopsy gun (BARD MAGNUM, Covington,
GA) and an 18-gauge Tru-cut biopsy needle. With the
patient in the lithotomy position the perineal area was
disinfected and bilateral local anesthesia was administered
with 10 ml of 2% lidocaine solution. The 8-core based
biopsy strategy was as follows: six cores were obtained
from the peripheral zone (PZ) consisting of the para-
midline, the middle and the lateral part, in addition to two
cores from the transition zone (TZ) in each lobe. In
patients with abnormalities on baseline or postcontrast
ultrasonography, 2 to 4 additional cores were sampled
targeting the abnormalities. During the biopsy, the probe
was rotated and angulated to the desired sagittal plane and
the needle was introduced on the same plane. After the
biopsy gun was fired, the probe was switched to a convex
transducer to detect the biopsy needle and the most closely
corresponding transverse images with the same gland
morphologic findings in postcontrast images were
reproduced and saved for further correlation with regions
of interest (ROIs). To facilitate the spatial correlation of the
contrast and biopsy images, similar depth and focus
settings were used to obtain similar transverse images (Fig.
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Fig. 2. Figures showing method of image interpretation.
A. Postcontrast image of prostate gland of 78-year-old man with
elevated prostate specific antigen level of 7.3 ng/ml, substantial
enhancement was found in right peripheral zone (arrow). 
B. Region of interest was drawn to fit abnormality of postcontrast
image. 
C. Time intensity curve of region of interest. 
C1).
All specimens were marked as to the site of origin and
analyzed separately. The pathological findings were
categorized as malignant with an assigned Gleason score
for each biopsy core, prostatic intraepithelial neoplasia,
benign prostate hyperplasia, and inflammation. Prostate
cancers with a Gleason score of 7 or above were catego-
rized as high grade tumors while the rest were categorized
as low grade tumors. 
Image Interpretation 
All contrast-enhanced ultrasound data were analyzed on
the workstation using the Axius ACQ software (TOMTEC,
Germany) by one radiologist who was blinded to all
clinical and pathological information. The suspicion of
carcinoma included the presence of an echotexture
abnormality or contour deformity on grayscale images
consisting of an increased or asymmetric flow pattern on
Doppler images and substantial or heterogeneous enhance-
ment on postcontrast images. For abnormal ultrasound
findings above, ROIs were drawn to fit the sonographic
abnormalities (Fig. 2). The ROIs were also drawn for each
octant systematic biopsy site and the diameters were set to
approximately 4 mm. The spatial correlation of the biopsy
site and the ROI placement was based on the reproduced
transverse images of the biopsy needle (Fig. 3). The time
intensity curve was reconstructed for each ROI and the
curve characteristics were described using the hemody-
namic indices: arrival time (AT), is the time when the
signal in the ROI has grown by 20% (in seconds), time-to-
peak (TTP), indicates the moment of maximum enhance-
ment (in seconds), peak intensity (PI), shows the value of
the maximum intensity in the ROI that occurs after time
zero (in dB). 
Statistical Analysis 
Differences between two groups (high grade and low
grade cancer) were analyzed using student’s t-test or
Mann-Whitney test. A Chi-square test was used to
compare the rate between groups. Spearman correlation
Zhu et al.
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Fig. 3. Figures demonstrating correlation biopsy site and region of
interest placement.
A. Biopsy site of middle part of left peripheral zone on reproduced
transverse image. 
B. Region of interest was placed over biopsy site. 
C. Time intensity curve of region of interest. 
Ccoefficients were calculated to assess whether there is a
correlation between the hemodynamic indices and biopsy
Gleason score. P-values less than 0.05 were considered
statistically significant, and all statistical analyses were
performed using SPSS version 13.0 (SPSS, Chicago, IL). 
RESULTS
Among the 103 patients tested, the prostate biopsies
revealed 41 patients with prostate cancer and 62 patients
with non-malignant prostate disease. Of the 62 patients
with non-malignant prostate disease, 58 enrolled subjects
had a PSA velocity < 10% after a one-year follow-up. Two
of the patients had noticeably elevated serum PSA levels
during a follow-up examination (41.12, 11.64 ng/ml before
the biopsy and 97, 25.13 ng/ml after one-year follow-up).
In addition, two patients were lost in the follow-up and
were excluded. Thus, we excluded these four patients. In
58 non-malignant patients that underwent prostate
biopsies, 38 revealed a benign prostate hyperplasia,
whereas 20 were identified as having a benign prostate
hyperplasia with inflammation cell infiltration. 
In total, the prostate biopsies revealed 154 prostate
cancer lesions in 41 prostate cancer patients, including 29
Gleason score 9 lesions, 29 Gleason score 8 lesions, 65
Gleason score 7 lesions, and 31 Gleason score 6 lesions. In
addition, 125 prostate cancer lesions were in the PZ and
29 were in the TZ. Also, in the 154 prostate cancer lesions,
47 were biopsy-proven malignant sonographic abnormali-
ties and 107 were positive systematic cores. The clinical
characteristics of the patients were described in Table 1. 
Significant differences in the hemodynamic indices were
observed between the biopsy sites of non-malignant
prostate disease patients and prostate cancer lesions (Table
2). The characteristics of the hemodynamic indices of the
biopsy sites of non-malignant patients, low-grade prostate
cancer lesions, and high-grade lesions were described in
Table 3. High-grade tumors showed earlier enhancement
and earlier arrival of peak enhancement than low-grade
tumors. No significant difference for the PI was observed
between two groups (p = 0.158). Moreover, no significant
differences were found in hemodynamic indices between
the biopsy sites of non-malignant patients and low-grade
prostate cancer lesions.
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Table 1. Clinical Characteristics of Patients 
Variable Non-Malignant Patients Prostate Cancer Patients P value
No. of patients 58 41
Age years mean ± SD (range) 67.76 ± 8.91 (45-83) 73.61 ± 6.39 (59-86) < 0.001
#
PSA ng/ml mean ± SD (range) 08.44 ± 4.10 (0.30-16.80) 26.00 ± 28.54 (4.27-100) < 0.001
#
PSAD ng/ml per ml mean±SD (range) 00.20 ± 0.13 (0.01-0.56) 00.69 ± 0.82 (0.1-3.8) < 0.001
#
DRE (%) 10 (17%) 22 (54%) < 0.001*
Note.─ *P value by Chi-square, 
#P values by Mann-Whitney test, PSA = prostate specific antigen, PSAD = PSA density, DRE = digital rectal 
examination
Table 2. Comparison of Hemodynamic Indices between Biopsy Sites of Non-Malignant Patients and Prostate Cancer Lesions
Variable Non-Malignant Prostate cancer  P value
AT (sec) mean ± SD 23.36 ± 6.76 21.15 ± 4.78 < 0.001
TTP (sec) mean ± SD 31.62 ± 8.47 28.56 ± 6.36 < 0.001
PI, dB mean ± SD 07.69 ± 4.19 09.70 ± 4.01 < 0.001
Note.─ P value by student’s t-test, AT = arrival time, TTP = time-to-peak, PI = peak intensity, sec = second
Table 3. Comparison of Hemodynamic Indices between Biopsy Sites of Non-Malignant Patients, Low-Grade Prostate Cancer
Lesions and High-Grade Prostate Cancer Lesions
Non-Malignant
Low-Grade  High-Grade  P value P value  P value 
Variable
(Group 1)
Prostate Cancer Prostate Cancer (Group 1  (Group 2  (Group 1 
(Group 2) (Group 3) versus 2) versus 3) versus 3)
AT (sec) mean±SD 23.36 ± 6.76 23.59 ± 5.88 20.53 ± 4.26 0.982 0.001 < 0.001
TTP (sec) mean±SD 31.62 ± 8.47 31.65 ± 7.72 27.78 ± 5.75 0.854 0.002 < 0.001
PI, dB mean±SD 07.69 ± 4.19 08.79 ± 4.55 09.92 ± 3.85 0.161 0.158 < 0.001
Note.─ P value by student’s t-test, AT = arrival time, TTP = time-to-peak, PI = peak intensityProstate cancer lesions located in the PZ were analyzed
separately (Table 4). In addition to shorter AT and TTP,
high-grade PZ tumors had a higher PI than low-grade
tumors (p = 0.009), while low-grade tumors in the PZ also
had higher PI than the PZ of non-malignant patients (p =
0.022). The scatter plot diagrams of the PZ hemodynamic
indices were shown in Figure 4. The correlations between
the PZ prostate cancer Gleason score and hemodynamic
indices were analyzed and the results indicated an increase
in PZ cancer Gleason score with increasing PI and a
decrease in AT and TTP (Spearman correlation coefficient
0.223, -0.335 and -0.351, respectively) (p = 0.013, 
< 0.001 and < 0.001 respectively). 
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Table 4. Comparison of Hemodynamic Indices between PZ Biopsy Sites of Non-Malignant Patients, Low-Grade PZ Prostate
Cancer Lesions and High-Grade PZ Prostate Cancer Lesions
Non-Malignant  Low-Grade PZ  High-Grade PZ  P value P value P value 
Variable PZ Prostate Cancer Prostate Cancer (Group 1  (Group 2  (Group 1 
(Group 1) (Group 2) (Group 3) versus 2) versus 3) versus 3)
AT, s mean±SD 24.48 ± 6.95 24.13 ± 6.25 20.75 ± 4.40 0.808 0.002 < 0.001
TTP, s mean±SD 32.27 ± 8.68 31.36 ± 7.83 27.59 ± 5.74 0.617 0.008 < 0.001
PI, dB mean±SD 05.78 ± 2.49 07.02 ± 3.45 09.16 ± 3.57 0.022 0.009 < 0.001
Note.─ P value by student’s t-test, AT = arrival time, TTP = time-to-peak, PI = peak intensity, PZ = peripheral zone
AB
Fig. 4. Scatter plot diagram of peripheral zone hemodynamic
indices.
A. Scatter plot diagram shows peak intensity versus peripheral
zone pathology findings, columns represent mean value and error
bars indicate standard deviation. 
B. Scatter plot diagram shows arrival time versus peripheral zone
pathology findings, columns represent mean value and error bars
indicate standard deviation. 
C. Scatter plot diagram shows time-to-peak versus peripheral zone
pathology findings, columns represent mean value and error bars
indicate standard deviation. 
CDISCUSSION
One of the most challenging characteristics of prostate
cancer is its variable biologic aggressiveness. Prostate
cancer tends to have increased vascularity compared to
healthy prostatic tissue due to the formation of new vessels
or an increase in the capacity of existing vessels. Wilson
and his colleagues revealed that prostate cancer lesions
with a higher Gleason score had a higher degree of
vascularity (1). Further studies also concluded that
microvessel density was related to pathological stage,
disease recurrence, and disease specific survival (11-13).
Contrast-enhanced ultrasonography, which is useful in
assessing microvessel density, shows its potential value in
predicting prostate cancer Gleason score. 
Recent studies suggested that contrast-enhanced
ultrasonography was more sensitive for the detection of
clinically significant prostate cancer. Mitterberger and his
colleagues (10) performed contrast-enhanced color
Doppler targeted biopsies plus 10-core systematic biopsies
in 690 patients suspected of having prostate cancer.
Contrast-enhanced color Doppler targeted biopsies
detected significantly higher Gleason scores compared with
systematic biopsies. The author concluded that contrast-
enhanced color Doppler biopsies seemed to be helpful in
the grading of prostate cancer. The development in
computer software provided the ability to reconstruct
time-intensity curves and hemodynamic indices. In a
retrospective study, Goossen et al. (14) found that the
minimal time to the peak was the most predictive parame-
ter for localization of the prostate cancer lesions, but the
correlation between prostate cancer Gleason score and
hemodynamic indices was not included in their study. 
Compared with Doppler imaging employed by most
previous studies (7-9, 14), the CPS harmonic imaging used
in this study recognizes and processes the unique nonlinear
fundamental and higher order harmonic signals generated
by the contrast agent, thus allowing for a significant
Contrast-Enhanced Harmonic US for Prostate Cancer Aggressiveness Evaluation
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Fig. 5. High-grade versus low-grade peripheral zone prostate
cancers.
A. Postcontrast image and time intensity curve of prostate cancer
lesion with Gleason score of 5 + 4 (arrows) in 73-year-old man with
elevated prostate specific antigen level of 31 ng/ml, while hemody-
namic indices arrival time, time-to-peak and peak intensity of lesion
were 15 s, 23 s and 20.5 dB respectively. 
B. Postcontrast image and time intensity curve of prostate cancer
lesion with Gleason score of 3 + 4 (arrows) in 78-year-old man with
elevated prostate specific antigen level of 7.3 ng/ml, while hemody-
namic indices arrival time, time-to-peak and peak intensity of lesion
was 22 s, 26 s and 9.2 dB, respectively. 
C. Postcontrast image and time intensity curve of prostate cancer
lesion with Gleason score of 3 + 3 (arrows) in 70-year-old man with
elevated prostate specific antigen level of 4.8 ng/ml, while hemody-
namic indices arrival time, time-to-peak and peak intensity of lesion
were 25 s, 35 s and 7 dB, respectively. 
Cincrease in the specificity of contrast agent-to-tissue, even
at low mechanical index power levels. Furthermore, gray-
scale CPS imaging is less affected by motion noise and
blooming artifact. Therefore, CPS harmonic imaging is
more sensitive in depicting neovascularity associated with
prostate cancer. 
This study focuses evaluating the utility of contrast-
enhanced ultrasonography for predicting prostate cancer
aggressiveness. The results revealed that in high-grade
tumors, the contrast-enhanced blood arrived, and was
distributed to the tissue more quickly than in low-grade
tumors. This might be related to the development of
immature vascularity associated with the growth of
malignancies. No significant difference was observed for
the PI between the low and high-grade tumor groups.
When TZ prostate cancer lesions were excluded, we found
that high-grade PZ tumors had a higher PI than low-grade
PZ tumors, in addition to shorter AT and TTP (Fig. 5). This
might be explained by the fact that the TZ of the prostate
gland often showed hypervascularity because of the
changes of the benign prostatic hyperplasia. Moreover, PZ
prostate cancer lesions with higher Gleason scores had a
higher degree of vascularity, while the parameter PI was
thought to be associated with the blood volume in the
area. We also demonstrated that there was a trend toward
increasing the PZ prostate cancer Gleason score with
increasing PI and decreasing AT and TTP, while the
Spearman correlation coefficient was 0.223, -0.335, and 
-0.351, respectively. The correlation coefficients indicated
that there were overlaps between the hemodynamic
indices at various Gleason score levels; however, this
might reflect methodologic and physiologic variations. 
In this study, a different instrument was used to perform
transperineal prostate biopsies, which is the routine biopsy
protocol at our institute. For the transperineal protocol, the
cores from any given area of the prostate can be attained
with this procedure because the needle is freely handed,
thus allowing for better targeting of the abnormal findings
in the lateral part of the gland (15). Furthermore, transper-
ineal cores were taken along a longitudinal plan parallel to
the rectum, while the whole core was obtained from the
PZ (16). In contrast, transrectal cores are taken along a
plane crossing the PZ and often involving the TZ in the
distal end of the core, especially in larger prostates where
the PZ is only a thin layer compressed by the TZ (15). This
may result in the overestimation of the PZ prostate cancer
lesions and misplacement of the ROI. The transfer of the
abnormalities of the endfire probe onto the image of the
biplane probe used for prostate biopsies was currently a
manual process that would be susceptible to localization
errors. To minimize these errors, 2 to 4 additional cores
were sampled to target the abnormalities. Moreover, the
location of each biopsy site was confirmed at transverse
images after the biopsy gun was fired. 
Our study did have some limitations which may have
caused the overlaps between the hemodynamic indices at
various Gleason score levels. First, the contrast-enhanced
ultrasonography was performed with an endfire probe,
while the prostate biopsy was performed with a biplane
probe. The probe transfer increased the likelihood of
introducing localization errors. Second, the ROIs averaging
with surrounding tissue might have contributed to scatter
in the hemodynamic indices, especially in smaller lesions.
Third, although the pressure of the transrectal probe was
controlled to a minimum by the elimination of gas between
the rectal wall and the probe to obtain more perfusion of
the paramidline segment, relative hypovascularity in the
prostate cancer lesions of paramidline segment was
observed in some cases. This can be partially attributed to
the near-field effect, which is difficult to avoid. Finally, the
arrival and distribution of contrast-enhanced blood to the
prostate gland is affected by the circulation system of each
patient, which cannot be controlled and represents a
source of variation in the results. 
Moreover, in our study, the biopsy Gleason score was
used to correlate with the CPS indices. Although a prostate
biopsy Gleason score is widely used in assessing prostate
cancer aggressiveness, a biopsy specimen still represents a
limitation for the assessment of all cancer sites and grades.
Gleason score is sometimes under or upgraded after radical
prostatectomy (17, 18). However, the result of this present
study was based on the correlation between the ROI and
biopsy site, not all the cancer lesions, thus was less affected
by under or upgrading.
In conclusion, CPS harmonic ultrasonography can be
used to image the hemodynamic behavior of prostate
cancer and the CPS imaging indices correlate with the
pathologic Gleason scores. Although there are overlaps
between hemodynamic indices at various Gleason score
levels, the results still suggests a measurable potential for
the use of CPS harmonic ultrasonography for the assess-
ment of noninvasive prostate cancer aggressiveness.
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